TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18695765

Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib vaccine co-administered with rotavirus vaccine
Number of subjects: 2464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study: 15041394

Group type: EXPERIMENTAL
Intervention: Daclizumab 50 mg (two doses on day 0 and day 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Daclizumab 25 mg (two doses on day 0 and day 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Basiliximab 20 mg (two doses on day 0 and day 4)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No antibody induction
Number of subjects: 54
Study: 12511059

Group type: EXPERIMENTAL
Intervention: Enhanced methadone treatment primarily cognitive‐behavioral therapy (CBT) for cocaine use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 0
Study: 9821596

Group type: EXPERIMENTAL
Intervention: Swanson prostheses
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sutter prostheses
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 7545060

Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 1362
Study: 2571308

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1172753

Group type: EXPERIMENTAL
Intervention: 10% potassium chloride solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Waxy-matrix potassium chloride tablet
Number of subjects: 20
Study: 30242918

Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 27873502

Group type: EXPERIMENTAL
Intervention: Intravenous urapidil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 180
Study: 25927360

Group type: EXPERIMENTAL
Intervention: JAIVAC-1 (10 μg, 25 μg, and 50 μg of each antigen)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (standard dosage)
Number of subjects: 45
Study: 23100318

Group type: EXPERIMENTAL
Intervention: Oxford chair group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional method group
Number of subjects: 60
Study: 21781475

Group type: EXPERIMENTAL
Intervention: 15 ± 5 mg/kg salt iodization
Number of subjects: 3

Group type: COMPARATOR
Intervention: 35 ± 5 mg/kg salt iodization
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thyroid volume measurement
Number of subjects: 3
Study: 19259615

Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 150
Study: 16952155

Group type: EXPERIMENTAL
Intervention: CIN1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPV cellular changes
Number of subjects: 0
Study: 15248939

Group type: EXPERIMENTAL
Intervention: Four-layer bandage (4LB)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Short-stretch bandage (SSB)
Number of subjects: 387
Study: 11736779

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1 microg x kg(‐1) intra‐operatively
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intramuscular morphine 100 microg x kg(‐1) at induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 9416883

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 965
Study: 8107618

Group type: EXPERIMENTAL
Intervention: Progesterone administered by nasal spray (34 mg daily for 5-7 days) with oral estrogens for 3-4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Progesterone administered by nasal spray (34 mg daily for 6 days) without estrogens
Number of subjects: 10
Study: 3632375

Group type: EXPERIMENTAL
Intervention: Progabide (45 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Progabide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31221949

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo ESWT
Number of subjects: 45
Study: 29698021

Group type: EXPERIMENTAL
Intervention: Super Low (4% ABV for wine, 1% ABV for beer)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Low (8% ABV for wine, 3% ABV for beer)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Regular (no verbal descriptors of strength)
Number of subjects: 264
Study: 27019334

Group type: EXPERIMENTAL
Intervention: Intervention group (psychosocial program tailored to prevent depression)
Number of subjects: 3326

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 3326
Study: 24115373

Group type: EXPERIMENTAL
Intervention: Pre-FS adropin concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-FS adropin concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-FS adropin concentrations (kcal adjusted for body size)
Number of subjects: 0
Study: 22859794

Group type: EXPERIMENTAL
Intervention: Biocompatible PD solutions
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional PD solutions
Number of subjects: 185
Study: 20523212

Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 60
Study: 18787222

Group type: EXPERIMENTAL
Intervention: Daclizumab (intravenous loading dose, 2 mg/kg, then 1 mg/kg) every 2 weeks, added to stable-dose TAA through Week 12.
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo every 2 weeks, added to stable-dose TAA through Week 12.
Number of subjects: 115
Study: 15116008

Group type: EXPERIMENTAL
Intervention: Dideco Lilliput 1 Oxygenator with 750 mL priming volume
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medtronic Minimax Oxygenator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dideco Lilliput 1 Oxygenator with 450 mL priming volume
Number of subjects: 40
Study: 11339517

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 599

Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 599
Study: 9039945

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1500 IU of anti‐HBs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular immunoglobulin (1000 IU of anti‐HBs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Switch from intravenous to intramuscular immunoglobulin
Number of subjects: 12
Study: 7951343

Group type: EXPERIMENTAL
Intervention: 2.5 g dipyrone
Number of subjects: 104

Group type: COMPARATOR
Intervention: 100 mg tramadol
Number of subjects: 104

Group type: COMPARATOR
Intervention: 20 mg butylscopolamine
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 104
Study: 3306163

Group type: COMPARATOR
Intervention: Propranolol (20 mg every 6 hours)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg followed by 0.25 mg daily)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 123
Study: 28574274

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transition strategies from intravenous to oral P2Y12 receptor antagonists
Number of subjects: 0
Study: 29414986

Group type: EXPERIMENTAL
Intervention: Reduced water levels in troughs
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (normal water levels)
Number of subjects: 35
Study: 27714002

Group type: EXPERIMENTAL
Intervention: Nutritional counseling with currants (two fruit servings, 36 g per day)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Nutritional counseling (Control arm)
Number of subjects: 55
Study: 24856557

Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine (SAMe) 1600-3200mg/daily
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20mg/daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 22156333

Group type: EXPERIMENTAL
Intervention: IV patient-controlled analgesia (PCA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional IV nurse‐administered as‐needed (PRN) therapy
Number of subjects: 80
Study: 20477775

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17404000

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily for 5 days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Doxycycline (100 mg twice daily for 5 days)
Number of subjects: 92
Study: 16376202

Group type: EXPERIMENTAL
Intervention: Upper-limb aerobic exercise training (UL-Ex)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lower-limb aerobic exercise training (LL-Ex)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-exercise training control group
Number of subjects: 104
Study: 12555509

Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg od)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg od)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 200
Study: 9430987

Group type: EXPERIMENTAL
Intervention: AAACa (200 mg calcium)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Milk (200 ml after breakfast, supper, and at bedtime)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no calcium supplement)
Number of subjects: 8
Study: 8007703

Group type: EXPERIMENTAL
Intervention: 4-HPR (Fenretinide)
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: 5-year administration of 4-HPR
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: 4-HPR
Number of subjects: 2972
Study: 2831594

Group type: EXPERIMENTAL
Intervention: Immunotherapy with a non-specific adjuvant
Number of subjects: 219
Study: 31566800

Group type: EXPERIMENTAL
Intervention: Time to first analgesic medication
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Emergency department length of stay (ED LOS)
Number of subjects: 727
Study: 28581323

Group type: EXPERIMENTAL
Intervention: Givers practiced 5 acts of kindness for a personalized list of Receivers over 4 weeks
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Receivers of kindness from Givers
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Givers' prosocial acts
Number of subjects: 111

Group type: COMPARATOR
Intervention: Controls (no specific intervention mentioned)
Number of subjects: 111
Study: 26674366

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008
Study: 26093189

Group type: EXPERIMENTAL
Intervention: Risk-based screening strategy (age <= 25, multiple sexual partners, inconsistent condom use, history of prior STI)
Number of subjects: 5087

Group type: COMPARATOR
Intervention: Age-based screening (age <= 25)
Number of subjects: 5087

Group type: COMPARATOR
Intervention: Age/partner-based screening (age <= 25 and/or multiple sexual partners)
Number of subjects: 5087

Group type: EXPERIMENTAL
Intervention: Risk-based screening strategy
Number of subjects: 5087
Study: 23846486

Group type: EXPERIMENTAL
Intervention: Polyphenon E (400 mg or 800 mg of total EGCG daily, administered in split doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 20
Study: 21831559

Group type: EXPERIMENTAL
Intervention: Motivational referral condition (MRC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MRC plus incentive (MRC + I)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard referral condition
Number of subjects: 113
Study: 18419948

Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg/kg intravenous injection based on psychological nursing intervention
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention
Number of subjects: 87

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 87
Study: 17137979

Group type: EXPERIMENTAL
Intervention: On-axis clear corneal incision (CCI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Temporal clear corneal incision (CCI)
Number of subjects: 62
Study: 12662955

Group type: EXPERIMENTAL
Intervention: Educational reminder messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10685585

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia and low-intensity exercise
Number of subjects: 6
Study: 9506266

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin prophylaxis
Number of subjects: 0
Study: 8352874

Group type: EXPERIMENTAL
Intervention: Problem-based Primary Care Curriculum (PCC) track
Number of subjects: 675

Group type: COMPARATOR
Intervention: Conventional track
Number of subjects: 675

Group type: COMPARATOR
Intervention: High-risk students in the conventional track
Number of subjects: 675
Study: 31695534

Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo cocktail
Number of subjects: 13
Study: 29735468

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection 150mg (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection 200mg (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurbiprofen axetil injection 100mg (Group A)
Number of subjects: 0
Study: 26999730

Group type: EXPERIMENTAL
Intervention: Advanced intervention (group B)
Number of subjects: 2379

Group type: COMPARATOR
Intervention: Standard intervention (group A)
Number of subjects: 2379
Study: 24283249

Group type: EXPERIMENTAL
Intervention: Telerehabilitation assessment of spinal posture, active movements of the lumbar spine, and the SLR test
Number of subjects: 26

Group type: COMPARATOR
Intervention: Face‐to‐face physical therapist assessment
Number of subjects: 26
Study: 21347523

Group type: EXPERIMENTAL
Intervention: 12-week progressive resistance exercise training protocol (n = 27)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standardized therapeutic exercise protocol (n = 25)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nerve sparing neck dissection procedures
Number of subjects: 52
Study: 20305847

Group type: EXPERIMENTAL
Intervention: Acrylic-based resilient liner (ARL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional acrylic resin (CAR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: New complete dentures
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Duration of edentulism
Number of subjects: 74
Study: 17448631

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15788975

Group type: EXPERIMENTAL
Intervention: Rotational Angiography (RA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional Angiography (TA)
Number of subjects: 31
Study: 12871780

Group type: EXPERIMENTAL
Intervention: High serum syndecan‐1 level (>212 microg/l)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low serum syndecan‐1 level (≤212 microg/l)
Number of subjects: 88
Study: 10329064

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 20536

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily)
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo (matching placebo tablets for simvastatin)
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Placebo (matching placebo capsules for vitamins)
Number of subjects: 20536

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 20536
Study: 8936246

Group type: EXPERIMENTAL
Intervention: Post-unplanned cesarean birth (n = 122)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Pregnant women with diabetes (n = 55)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Hysterectomy (n = 109)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Very low birthweight (VLBW) infants (n = 79)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Elderly with medical cardiac DRGs (n = 142)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Elderly with surgical cardiac DRGs (n = 134)
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Cesarean and infants, hysterectomy and surgical elderly groups
Number of subjects: 764
Study: 1929608

Group type: EXPERIMENTAL
Intervention: Indomethacin (Indo) 150 mg administered intravenously on days 0 to 5
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP-5) administered subcutaneously on days 0, 2, 4, and Indomethacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (PC)
Number of subjects: 60
Study: 6753893

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg three times a day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 15 mg three times a day
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Combination of captopril and hydrochlorothiazide
Number of subjects: 207

Group type: COMPARATOR
Intervention: Hydrochlorothiazide alone
Number of subjects: 207
Study: 31904682

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 5407

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 5407
Study: 30093398

Group type: EXPERIMENTAL
Intervention: Dasatinib therapy
Number of subjects: 2712
Study: 28378369

Group type: EXPERIMENTAL
Intervention: ONO-4053
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 26096461

Group type: EXPERIMENTAL
Intervention: Jitai tablets
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jitai tablets and Placebo
Number of subjects: 64
Study: 24259652

Group type: EXPERIMENTAL
Intervention: LWD + CMM (Living Well With a Disability + Collaborative Medication Management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LWD only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 21843832

Group type: EXPERIMENTAL
Intervention: Passive static stretching regimen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mock passive stretching regimen
Number of subjects: 22
Study: 19006657

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation
Number of subjects: 36
Study: 17720383

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 30

Group type: COMPARATOR
Intervention: CABG and OPCAB
Number of subjects: 30
Study: 15108078

Group type: EXPERIMENTAL
Intervention: Exxcel grafts
Number of subjects: 94

Group type: COMPARATOR
Intervention: Gore-tex grafts
Number of subjects: 94
Study: 11236936

Group type: EXPERIMENTAL
Intervention: L10M regimen
Number of subjects: 195

Group type: COMPARATOR
Intervention: DAT (daunomycin, cytosine arabinoside, 6-thioguanine) and escalating methotrexate (MTX) and L-asparaginase (L-asp)
Number of subjects: 195

Group type: COMPARATOR
Intervention: DAT/MTX/L-asp regimen
Number of subjects: 195
Study: 9633704

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment (1,000 mg IV infusion followed by 200 mg/day subcutaneously for 16 weeks)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 45
Study: 7541258

Group type: EXPERIMENTAL
Intervention: octreotide 0.2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: octreotide 0.1 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 3291150

Group type: EXPERIMENTAL
Intervention: Sotalol therapy starting with 40 mg and increasing to 120 mg, followed by the maximal dose tolerated every 6 hours for 72 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30343858

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 mg methylprednisolone acetate)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Night splint
Number of subjects: 234
Study: 28156011

Group type: COMPARATOR
Intervention: Single doses of LY2979165 (20-150 mg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Multiple once-daily doses of LY2979165 (20-400 mg)
Number of subjects: 114
Study: 25681277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: AZD5069 50 mg bid
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: AZD5069 80 mg bid
Number of subjects: 87
Study: 23441793

Group type: EXPERIMENTAL
Intervention: Nanotite (N) implants
Number of subjects: 7

Group type: COMPARATOR
Intervention: Osseotite (O) implants
Number of subjects: 7
Study: 21713440

Group type: EXPERIMENTAL
Intervention: iobitridol (Xenetix® 300)
Number of subjects: 146

Group type: COMPARATOR
Intervention: iodixanol (Visipaque® 270)
Number of subjects: 146
Study: 18312423

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Baseline assessments
Number of subjects: 35
Study: 16569171

Group type: EXPERIMENTAL
Intervention: General questioning
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Specific questioning
Number of subjects: 83

Group type: COMPARATOR
Intervention: Repeated questioning (interview at 3 months)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Prior knowledge assessment
Number of subjects: 83
Study: 12502473

Group type: EXPERIMENTAL
Intervention: Laser-assisted uvulopalatoplasty (LAUP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 45
Study: 10784627

Group type: EXPERIMENTAL
Intervention: Mitoxantrone, etoposide, and cyclosporine (MEC) therapy: mitoxantrone 6 mg/m2/d for 5 days, etoposide 60 mg/m2/d for 5 days, and CSA 10 mg/kg for 2 hours followed by 30 mg/kg/d as a continuous infusion for 98 hours.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) levels greater than 2,400 ng/mL.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Toxicities associated with MEC therapy.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MDR1 status evaluation.
Number of subjects: 66
Study: 8895285

Group type: EXPERIMENTAL
Intervention: M6G 125 micrograms
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: M6G 100 micrograms
Number of subjects: 75

Group type: COMPARATOR
Intervention: Morphine sulfate 500 micrograms
Number of subjects: 75